**Core Concept:**
Basiliximab is a monoclonal antibody, a type of immunoglobulin, which is used as an immunosuppressive agent in organ transplantation. It belongs to the class of drugs known as calcineurin inhibitors, which work by inhibiting the calcineurin-NFAT pathway, thus suppressing T-cell activation and preventing organ rejection.

**Why the Correct Answer is Right:**
Basiliximab is a monoclonal antibody against the interleukin-2 receptor (IL-2R), a protein expressed on the surface of activated T cells. By binding to IL-2R, basiliximab prevents IL-2 binding, which is essential for T cell proliferation and activation. This results in immunosuppression and reduced organ rejection.

**Why Each Wrong Option is Incorrect:**
A. This option is incorrect because basiliximab is not against the angiotensin-converting enzyme (ACE). ACE inhibitors are a different class of drugs used for hypertension and heart failure, while basiliximab is an immunosuppressive agent for organ transplantation.
B. This option is incorrect because basiliximab is not against the angiotensin II receptor (AT1R). Angiotensin II is a potent vasoconstrictor and hormone involved in the renin-angiotensin-aldosterone system (RAAS), while basiliximab is an immunosuppressive agent for organ transplantation.
C. This option is incorrect because basiliximab is not against the corticotropin-releasing hormone (CRH) receptor. CRH is a hormone involved in the hypothalamic-pituitary-adrenal axis, while basiliximab is an immunosuppressive agent for organ transplantation.
D. This option is incorrect because basiliximab is not against the interleukin-2 receptor (IL-2R). IL-2 is a cytokine involved in immune response, specifically activating T cells, while basiliximab is an immunosuppressive agent for organ transplantation.

**Clinical Pearl:**
Monoclonal antibodies like basiliximab are used in organ transplantation to prevent organ rejection by suppressing the immune response. By targeting specific immune system molecules, they help in maintaining a stable graft function and reducing the risk of organ rejection and infection.

**Correct Answer:** D. Interleukin-2 receptor (IL-2R)

Basiliximab is a monoclonal antibody that specifically targets the interleukin-2 receptor (IL-2R), a protein expressed on activated T cells. By binding to IL-2R, basiliximab prevents the binding of interleukin-2 to IL-2R, which is essential for T cell activation and proliferation. This inhibition of T cell activation contributes to immunosuppression and reduced risk of organ rejection in organ transplantation.